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Abstract
Background: It remains controversial how HCV coinfection influences the disease progression during HIV-1 infection. This
study aims to define the influence of HCV infection on the replication of HIV-1 and the disease progression in HIV-infected
former plasma donors (FPDs) naı ¨ve to ART.
Methodology/Principal Findings: 168 HIV-1-infected FPDs were enrolled into a cohort study from Anhui province in central
China, and thereafter monitored at month 3, 9, 15, 21 and 33. Fresh whole blood samples were used for CD4+ T-cell
counting. Their plasma samples were collected and stored for quantification of HIV-1 viral loads and for determination of
HCV and Toxoplasma. Out of 168 HIV-infected FBDs, 11.9% (20 cases), 80.4% (135 cases) and 7.7% (13 cases) were infected
with HIV-1 alone, HIV-1/HCV and HIV/HCV/Toxoplasma, respectively. During the 33-month follow-up, only 35% (7 out of 20
cases) HIV-1 mono-infected subjects remained their CD4+ T-cell counts above 200 cells/ml and retained on the cohort study,
which was significantly lower than 56% (75 out of 135 cases) for HIV/HCV group and 69% (9 out of 13 cases) for HIV/HCV/
Toxoplasma group (p,0.05). CD4+ T cells in HIV mono infection group were consistently lower than that in HIV/HCV group
(p=0.04, 0.18, 0.03 and 0.04 for baseline, month 9, month 21 and month 33 visit, respectively). In accordance with those
observations, HIV viral loads in HIV mono-infection group were consistently higher than that in HIV/HCV group though
statistical significances were only reached at baseline (p=0.04).
Conclusions/Significance: These data indicated HCV coinfection with HIV-1 is associated with the slower disease
progression at the very late stage when comparing with HIV-1 mono-infection. The coinfection of Toxoplasma with HIV and
HCV did not exert additional influence on the disease progression. It will be highly interesting to further explore the
underlying mechanism for this observation in the future.
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Introduction
The co-infection of hepatitis C virus (HCV) and HIV-1 may
result in the interaction between the two viruses and thereby alter
the disease course. Patients co-infected with HCV and HIV more
rapidly progress to cirrhosis than those with HCV alone [1], and
are at increased risk of death from the end-stage liver disease [2].
HAART therapy has been reported to reduce intrahepatic HCV
loads. Patients treated with regimen containing protease inhibitor
(PI) for at least 6 months had a three- to four-fold lower
intrahepatic HCV loads than that observed in patients who had
never received any ARV treatment of PI containing regimen or
had withdrawn for more than 6 months before the liver biopsy [3],
however, no difference was observed in the plasma HCV loads
among those groups [4]. It remains controversial how HCV
infection affects the disease course of HIV-1 infection. In the Swiss
Cohort Study HCV coinfection was independently associated with
a 21% reduction in the likelihood of increasing the CD4+ T-cell
counts by at least 50 cells/mL and with an increased risk of
progression to AIDS and to death among patients initiating
HAART [5], and higher HCV RNA levels were associated with
more CD4+ T-cell depletion in a prolonged observation (4 years)
[6]. In the Johns Hopkins cohort, no significant difference was
observed between HIV-1 mono-infection and HIV plus HCV co-
infection after controlling for the use and effectiveness of HAART
[7]. Interestingly, one study observed that immune recovery is
associated with a persistent increase in plasma HCV RNA,
especially for those with baseline CD4+ T-cell counts ,350 cells/
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response to HAART [8]. Currently, HIV-1 and HCV co-infection
is gradually being recognized as a separated entity from HIV-1 or
HCV mono-infections with an altered response to HAART and
requires special effort for care and treatment.
In China, HCV co-infection is frequently observed among HIV
infected patients, especial in patients of injecting drug users and
former plasma donors (FPDs) [9]. Unregulated commercial plasma
collection among farmers occurred between 1992 and 1995 in
central China, including Henan, Anhui and Shanxi provinces, and
caused the second major epidemic of HIV-1 infection in China.
Although this was eradicated by Chinese government by the end of
1995 [10], the practice of using contaminated blood collection
equipment or re-infusing pooled blood cells back to donors caused
rapid HIV-1 and HCV spreading among those FPDs [11–12].
HIV-1-infected FPDs represent a unique population to study the
natural disease progression of HIV-1 and HCV coinfections
because the outbreak of infection occurred within a narrowed
period and the vast majority of FPDs were infected with HIV-1 and
HCV from a common-source exposure to contaminated blood and
currently have had a .10 years infection history, any manifestation
from HIV-1 on HCV or from HCV on HIV-1 should have been
accumulated for more than a decade for observation.
We established an ART naı ¨ve cohort of HIV-1 and HCV co-
infection in FPDs and a 33-month longitudinal observation has
been carried out. In addition, to exclude the interference from
other pathogens, we further determined the influences of the
infections toxoplasma. Our observation will bring new insight to
the management of HIV/AIDS patients to reduce their morbidity
and mortality.
Materials and Methods
Establishment of study cohort
HIV-1-infected former plasma donors (FPDs) naı ¨ve to anti-
retroviral therapy in Fuyang prefecture city of Anhui Province in
central China were enrolled into this study. All participants donated
blood between 1992 and 1995 from their self-report and HIV+
individuals in the absence of blood donation history during that
period were excluded from our study cohort. Since this is a
conservative area and no other high-risk behaviors (such as drug
using or extramarital sexual contacts) were reported in this cohort,
their HIVinfection wereepidemiologicallyattributed to a common-
source exposure to contaminated blood during their practice of
blooddonation,whichincludedusingcontaminatedbloodcollection
equipment or re-infusing pooled blood cells back to donors.
Following approval by IRBs at China National Center for AIDS/
STD Control and Prevention and at Anhui Provincial Center for
Disease Control and Prevention, 294 HIV-1-infected FBD
volunteers naı ¨ve to anti-HIV and anti-HCV treatment were
screened in June, 2005 [13], including 77 cases with CD4+ T cells
,200 cells/ul and 217 cases with CD4+ T cells .200 cells/ml. Out
of 217 subjects with CD4+ T cells .200 cells/ml, 168 subjects were
willing to participate into a Cohort Study in September, 2005, and
have been successfully followed up either for 33 months or until
CD4+ T cells dropped below 200 cells/ml. All study participants
were coded and delinked from their personal information in this
study. Subjects whose CD4+ T cells dropped below 200 cells/ml
during our follow-up visit were referred to China CARES program.
The China CARES program is a comprehensive community-based
HIV/AIDS treatment, care, and prevention program. It was
launched in early 2003, and has been started in seven provinces in
Central China, including Anhui Province. The activities of this
program include advocacy, communication, preventive services,
voluntary counseling and testing, free treatment of opportunistic
infections, free antiretroviral therapy with the regiment
D4T+3TC+NVP, and community-based care and support.
Samples collection
Whole blood specimens were collected in sterile tubes using
EDTA as the anticoagulant. All samples were transferred to
laboratory within 12 hours after collection. Fresh whole blood
samples were used for CD4+ T-cell counting; and plasma samples
were stored at 220uC for HIV, HCV and taxoplasma testing.
Plasma samples were stored at 280uC for viral RNA extraction
and viral load detection.
Plasma Testing
HIV and HCV antibodies were tested by ELISA (Beijing
Wantai, Beijing, China). Toxoplasma Enzyme-linked immunosor-
bent assay (ELISA) kitswas from Haitai Biocompany (Guangdong,
China), the test determined the presence or absence of anti-T.
gondii immunoglobulin G (IgG), IgM antibodies. Serum samples
were assayed in duplicate. All assays were carried out according to
the manufacture’s instruction.
Quantitation of plasma HIV-1 viral loads
Viral RNA was isolated from 200 ml EDTA anticoagulated
plasma using a QIAamp Viral RNA kit (Qiagen, Germany) and
treated with DNase I on a spin column (DNase 1 set; Qiagen)
according to the manufacturer’s instructions. RNA was eluted in
60 ml AVE buffer and analyzed immediately. Real-time RT-PCR
was used to determine plasma viral load by amplification of a 102-
bp segment of the HIV-1 gag gene. The reaction composing and
condition were the same as the Manufacture’s Manual. Briefly,
Real-time RT-PCR was performed using Real-time RT-PCR Kit
(Shenzhen PG Biotech Co. China) in 10 ml reaction volume.
Cycling conditions were 30 min at 42uC, 3 min at 92uC, followed
by 5 cycles at 95uC for 10 s and 52uC for 20 s, and 72uC for 30 s.,
then another 40 cycles at 95uC for 5 s and 60uC for 30 s, and
40uC for 30 s. Reactions were performed in triplicate using a
COBAS AMPLICOR Analyzer. Results are expressed as HIV-1
RNA copies/ ml. The low limitation was 500 copies /ml.
Quantification of CD4+ T-Cell Counts
CD4+ T lymphocyte absolute counts can be accomplished with
single platform counting technologies employing cytometric
methods. All reagents were from Becton Dickinson (CA). Twenty
microliter antibodies (CD3-FITC/CD4-PE/CD45- PerCP) were
added into different TruCOUNT tubes, then 50 ml whole blood
was added into each TruCOUNT tube and mixtures were gently
vortexed at room temperature (18uC–25uC) in the dark for
20 minutes. Next, 450 ml1 6FACS lysing solution (Dilute
106FACS lysing solution with distilled water) was added into
each tube. The mixtures were incubated at 20uC–25uC in the dark
for 15 minutes, then run within 24 hours.
Statistical analysis
The Student’s t test was used to compare the HIV-1 viral load
and CD4+ T cells counts among different groups. Statistical
significance was defined as a p value of ,0.05.
Results
Characterization of the study cohort
It was estimated that about 1400 subjects were infected by HIV-
1 through the blood/plasma donation in Fuyang city of Anhui
HCV Co-Infection in HIV+ FBDs’
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have died from AIDS after more than a decade of HIV-1 infection
(data from local CDC report). Among the left 700 subjects (,50%)
survivals, .400 of them are receiving free ART, thus our cohort
(168 subjects) represents ,60% ART-free subjects in this region.
The demographic and epidemiological data of this cohort were
shown in Table 1. The high-risk factors for acquired HIV-1
infection were all from unregulated blood/plasma donation.
According to our previous study, HIV-1 strains prevalent in this
cohort were absolutely subtype B9, no viral property was identified
to be associated with low CD4+ T-cell counts and only two
possible paired transmission may occurred in the past according to
env gene sequencial analysis [14]. In addition, HCV 1b and 2a
subtypes dominated in FPDs population [9,15]. Out of the 168
PBDs, female subjects accounted for 43.1% and male subjects
accounted for 56.9%, and the average age was 44.2768.13.
HCV coinfection with HIV-1 associated with higher CD4+
T cell counts and lowering HIV viral loads at baseline
The overall CD4+ T-cell counts were negatively associated with
plasma viral loads (r=20.19) at baseline (Fig. 1a), and this
negative association were consistently observed during the follow-
up visits (data not shown), indicating that the viral replication is the
driving force for disease progression in the FBDs population. To
determine the effect of HCV coinfection with HIV-1 on the
disease progression, we compared HIV viral loads and CD4+ T-
cell counts at baseline among HIV-1 mono-infection (N=20
cases), dual infection of HIV plus HCV (N=135 cases) and triple
infection of HIV, HCV and toxoplasma (N=13 cases). The reason
to include the toxoplasma is to test whether the toxoplasma
coinfection with HIV and HCV could exact any additional effect
on disease progression.
As shown in figure 1b, CD4+ T-cell counts in the group of dual
infection (ranged from 206 to 928 cells/ml with a mean of 429
cells/ ml) was significantly higher than that in HIV mono-infection
(ranged from 237 to 639 cells/ul with a mean of 390 cells/ml)
(p=0.04). Similarly, CD4+ T-cell counts in the group of triple
infection (ranged from 245 to 577 cells/ul with a mean of 404
cells/ ml) also tended to be higher than that in HIV mono-infection
though statistical significance was not reached. In contrast, HIV-1
viral loads in the group of HIV/HCV dual infection (ranged from
under detection threshold to 5.77 with a mean of 4.15 log10
copies/ml plasma) were significantly lower than that in the group
of HIV mono-infection (ranged from under detection threshold to
5.24 with a mean of 4.43 log10 copies/ml plasma) (p=0.04), the
difference was further expanded between the triple infection of
HIV/HCV/Toxoplasma (ranged from 2.63 to 5.19 with a mean
of 4.03 log10 copies/ml plasma) and HIV-1 mono-infection,
however, no significant difference was observed between the dual
infection and triple infection groups (p=0.14) (Fig. 1c). Since
CD4+ T-cell count is the restraining factor and viral loads is the
driving force of disease progression, the ratio of CD4+ T cells to
viral loads will be likely a useful predictor for disease progression
and the lower ratio will be associated with faster disease
progression. Therefore, we examined the ratios of CD4+ T cells
to viral loads in log10 in our cohort. The ratio in the group of
HIV/HCV dual infection (ranged from 43.3 to 288.8 with a mean
of 110.6) were significantly higher than that in the group of HIV
mono-infection (ranged from 49.6 to 145.5 with a mean of 90.5)
(p=0.01), a similar difference was also observed between triple
infection (ranged from 51 to 213.8 with a mean of 114.3) and
mono-infection though statistical significance was not reached
(p=0.08) (Fig. 1d). These data indicate HCV coinfection with
HIV-1 may slow down disease progression of HIV-1 infection and
toxoplasma exerts highly limited effect on disease progression.
HCV coinfection with HIV-1 associated with slower
disease progression in cohort study
To further determine the influence of HCV coinfection with
HIV-1 on disease progression, we conducted a prospective cohort
study and calculated the percentages of individuals whose CD4+
T-cell counts remained .200 cells/ml and retained on the cohort
study. During 33 month follow up, the percentage of subjects with
CD4+ T-cell counts .200 cells/ml in this cohort decreased at
month 9 visit after entry (p,0.05) and continued to drop
afterwards (p,0.01 for all other visits comparing to baseline
data). At the final time point (33-month), only 51% of study
subjects were remained with CD4+T cells over 200 cells/ml
(Fig. 2a). We then examined the retaining rate by groups. As
shown in figure 2b, no significant differences of the percentages
among groups were observed during the first 9-month observation
though the difference did appear at month 9 visit. These data were
also supported by the observation from the baseline, 25.8% HIV-1
mono-infection cases (8 out 31 cases) had CD4+ T cells below 200
cells/ml, which is comparable to what observed in HIV/HCV dual
infection group (65 out of 253 cases, 25.7%). However, during the
prolonged observation (at month 15, month 21 and month 33
visits), significant less fractions of subjects from HIV/HCV dual
infection or HIV/HCV/Toxoplasma triple infection progressed
into AIDS stage defined as CD4+ T cells below 200 cells/ml
(Fig. 2b). At the month 33 follow-up, only 35% HIV-1 mono-
infected cases remained their CD4+ T-cell counts .200 cells/ml,
which is significantly lower than that observed 56% in HIV/HCV
dual infection group and 69% in HIV/HCV/Toxoplasma triple
infection group. Furthermore, absolute CD4+ T-cell counts in
HIV/HCV group were consistently higher than that in HIV
Table 1. Characterization of study cohorts.
Category Subcategory
HIV-1
monoinfection (N=20)
HIV/HCV dual
infection (N=135)
HIV/HCV/ Toxoplasma
triple infection (N=13) Total (N=168)
High-risk Blood/plasma donation Yes Yes Yes Yes
Drug using No No No No
Age (Mean6SD) 46.3611.1 4467.8 42.565.5 44.2768.13
Sex % Female (cases) 50 (10) 41.5% (56) 69.2% (9) 43.1% (75)
% Male (cases) 50 (10) 58.5% (79) 30.8% (4) 56.9% (99)
HIV-1 subtype B9 B9 B9 B9
doi:10.1371/journal.pone.0003992.t001
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month 9, month 21 and month 33 visit, respectively). 20% (27
cases) retained their CD4+ T-cell counts .600 in HIV/HCV
group even at month 33 visit whereas none does so in HIV mono-
infection group since month 21 visit (Fig. 2c, d and e). In
accordance with those observations above, HIV viral loads in
HIV/HCV group were consistently lower than that in HIV-1
group though statistical significances were only reached at baseline
(p=0.04) (Fig. 1c) and not other visits (Fig. 3). These data
indicated that HCV coinfection with HIV-1 may significantly slow
down the disease progression and this effect may only manifest at
the very late stage of HIV-1 infection.
HCV coinfection with HIV-1 may associate with slower
disease progression in the future in this cohort
As described above, the ratio of CD4+ T cells to viral loads may
be a useful predictor for disease progression of HIV-1 infection,
our baseline data (Fig. 1d) did correlate with the disease
progression data from the cohort study, the low ratio in HIV-1
mono-infection did progress faster than HIV/HCV group with
higher ratio. We thus further determined the ratio of CD4+ T cells
to viral loads at month 33 visit (Fig. 4). The ratio for HIV-1 mono-
infection group ranged from 25.5 to 137.5 with a mean of 94,
which was significantly lower than that in HIV/HCV dual
infection group (ranged from 26.1 to 380.1 with a mean of 134.7)
(p=0.014) and in HIV/HCV/Tox triple infection group (ranged
from 59 to 295.6 with a mean of 161.3) (p=0.046). We speculate
that HCV coinfection with HIV-1 may still significantly slow down
the disease progression in the cohort in the future.
Discussion
Though HIV-1 co-infection with HCV has been recognized to
facilitate the HCV replication and liver disease progression [16], it
remains to be determined on the role of HCV in the disease course
of HIV infection. A large cohort study of HIV-1-infected subjects
has demonstrated that HCV co-infection with HIV-1 accelerated
the progression to a new AIDS-defining clinical event or to death
through altering the immunological but not virological responses
Figure 1. Characterization of the cohort at baseline. a, the reverse association of CD4+ T-cell counts and viral loads in the study subjects at
baseline. The X axis indicated CD4+ T-cell counts (cells/ml), and Y axis indicated viral loads; GraphPad Prism 5 was used to generate the trend line and
r value. b and c, CD4+ T-cell counts and viral load among different groups at baseline. The X axis indicated different groups including HIV (HIV-1
mono infection), HIV/HCV (dual infection), and HIV/HCV/Tox (triple infection of HIV, HCV and toxoplasma). The Y axis indicated CD4+ T-cell counts
(1b) and viral load (1c); d, the ratio of CD4+ T cells to viral loads among different groups, the ratios were calculated by dividing CD4+ T-cell counts by
the value of viral loads in log10.
doi:10.1371/journal.pone.0003992.g001
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follow-up visits The X axis indicates the different time-points of sampling at baseline (BL), month 3 (3M), month 9 (9M), month 15 (15M), month 21
(21M), month 33 (33M) after enrollment; Y axis is the percentage of subjects whose CD4+ T-cell counts remained as .200; b, the percentage of
subjects remained with CD4+ T-cell counts .200 cells/ml during the follow-up visits among different groups as indicates in the figure, X and Y axis are
labeled identically to figure 2a;. * indicated p,0.05; c, d, e, CD4+ T-cell counts among different groups at month 9 (c), month 21 (d) and month 33 (e).
doi:10.1371/journal.pone.0003992.g002
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disease progression was coincident with HCV coinfection with
HIV-1 [17–20]. However, the association between HCV coinfec-
tion and AIDS-related disease progression was not defined in
EuroSIDA cohort study and several other studies [21–23].
Furthermore, HCV coinfection was correlated with long-term
non-progression status [24]. The controversial observations in this
field were best exemplified by two pairs of conflicting cohort
studies. The first is that a small cohort study for following up10
years in children defined that the HCV seropositive children had
twofold higher risk of progression to the development of AIDS
than HCV seronegative individual [25], whereas another study in
children who were vertically infected unambiguously demonstrat-
ed that significant less HIV-1/HCV coinfected children developed
AIDS than HIV-1 infected alone during a long-term observation
[26]. The second is that one study showed patients coinfected with
HCV genotype 1 had a faster rate of AIDS-related disease
progression [27], and another demonstrated that HCV genotype 1
was associated with long-term non-progression [28].
We took the advantage of HIV-1 infected FPDs cohort naı ¨ve to
ART for more than a decade and longitudinally monitored the
disease progression for almost three years. HIV-1-infected FPDs
represent a unique population to study the natural disease
progression of HIV-1 and HCV coinfections because the outbreak
of infection occurred within a narrowed period and the vast
majority of FPDs were infected with HIV-1 and HCV from a
common-source exposure to contaminated blood and currently
have had a .10 years infection history. Thus, this cohort are
composed of long-term non-progressors and late progressors with
epidemiological data support of a similar virological background
and a narrow-windowed time of initial infection, we believed that
these properties render our cohort is highly suitable for defining
the influence of HCV on HIV-1 infection. Our data demonstrated
that patients coinfected with HCV and HIV-1 was associated with
significant higher CD4+ T-cell counts than that in HIV-1 mono-
infection group, furthermore, co-infected individuals also tended
to have lower viral loads. Importantly, significant less percentage
of individuals in HIV/HCV coinfected group progressed into
AIDS stage defined as CD4+ T-cell counts ,200 cells/ml during
our observation. Finally, the HIV/HCV group has significant
higher ratios of CD4+ T cells to viral loads than that in HIV-1
mono-infection even at month 33 visit, which may indicate that
the HIV/HCV group will be likely to progress slower than the
HIV-1 mono-infection group in the future. Since our previous
virological study demonstrated that all participants were infected
by Thailand B clade, no viral property was identified to be
associated with disease progression and only two possible paired
transmission may occurred long time ago according to env gene
Figure 3. Viral loads at different follow-up visits (a) and among different groups (b, c, d) during observation. The X axis indicates the
different time-points of sampling at baseline (BL), month 3 (3M), month 9 (9M), month 15 (15M), month 21 (21M), month 33 (33M) after enrollment (a)
or indicates different groups (b, c and d), and Y axis indicates the viral load (log10 copies/ml).
doi:10.1371/journal.pone.0003992.g003
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HIV-1 monoinfection and HIV/HCV dual infection was highly
unlikely to be explained by different HIV-1 viral characterization.
Therefore, our data support previous reports in long-term non-
progressors and in a children cohort [26]. As previously reported
that the FBDs were infected by HCV 1b and 2a [9,15], it remains
unknown whether those particular genotypes could contribute to
the lower viral loads and slower disease progression observed in
this cohort.
As know, toxoplasma infection may speed up the AIDS-related
disease progression, particularly in those with their CD4+ T-cell
counts below 200 cells/mL [29–30]. Though we excluded patients
with CD4+ T-cell counts ,200 cells/mL at baseline from our
cohort study, however, toxoplasma may exert influence during our
follow-up visits when participants’ CD4+ T-cell counts dropped,
therefore, we performed toxoplasma testing and excluded
toxoplasma infected individual from the HIV-1 monoinfection.
To test whether toxoplasma infection could influence the HCV/
HIV-1 group, we compared the viral loads and CD4+ T-cell
counts between HIV-1/HCV dual infection group and HIV-1/
HCV/Toxoplasma triple infection, our data showed that
toxoplasma infection did not play a significant role in the viral
replication and disease progression.
Though it remains to be defined for the observed discrepancies
between our data and several previous reports, several factors
should be taken into consideration. The cohorts monitored by
previous studies might represent a mixture of patients at different
progression stages, our cohort represents a relative pure popula-
tion at very late stage. We hypothesized that HCV coinfection
may exert varied influences among different HIV-1-infected
individuals, patients with negative influences from HCV coinfec-
tion should have had a faster disease progression and may
dominate the observed results in cohort studies on patients at early
stage or on a mixture of patients at different stages since only a
small fraction of individuals will survive for a long term, whereas
patients with positive influences from HCV infection will gradually
become predominant in late stage. In accordance with this
hypothesis, our data showed that though CD4+ T cells counts in
HIV/HCV dual infection group were significantly higher and
viral loads were significantly lower than that in HIV-1 mono-
infection group at the baseline, a similar fraction of individuals in
both groups was observed at AIDS stage with CD4+ T cells ,200
cells/ul; it was only appeared at the last three visits that a
significant less fraction of HIV/HCV dual infected subjects
progressed into AIDS. A recent report also supported our
hypothesis, HCV coinfection with HIV-1 generated two distinct
patterns of immune responses, some patients had a limited
response to either virus whilst others made responses to a range of
HIV epitopes, interestingly, HCV responses were detected only in
those who made multiple responses to HIV epitopes. Lack of HIV-
specific T cells was associated with a decline in absolute CD4+ T-
cell counts between the time points [31]. These data indicated that
the host immune system either responded to both viruses or to
neither viruses during coinfection, the non-responded individuals
may reflect the faster progression group. Further cohort study at
very early stage will be required to validate this concept.
Overall, our data demonstrated that HCV coinfection with
HIV-1 was associated with slower disease progression in HIV-1
infected former plasma donors naive to ART at the very late stage.
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